Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

August 11, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 NSE Symbol: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 45/26-27 Our Reference No. 45/26-27 Dear Sir/ Madam, Sub: Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended (“SEBI LODR”): Glenmark Pharmaceuticals Ltd. (“the Company”) The Company and its subsidiaries are involved in legal proceedings, which are normal to our business. Often, these litigations are resolved through settlement agreements with the plaintiffs. As previously disclosed in its annual reports, there were multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S. against the Company’s subsidiary Glenmark Pharmaceuticals Inc., USA, (“Glenmark USA”) in connection with allegations of price-fixing, market allocation, and related anti-competitive conduct. Since 2016, Glenmark USA has been named in more than 35 complaints alleging that it, along with other manufacturers/suppliers of generic pharmaceutical products violated federal antitrust laws relating to their pricing of pharmaceutical products. The plaintiffs include classes of direct purchasers, end- payers, and indirect purchasers of generic drugs, as well as numerous private, direct-action plaintiffs, and 46 state attorneys general. Three complaints filed by Humana, Inc. (“Humana”) were included in the consolidated litigation. The plaintiffs, including Humana, allege both individual drug-specific conspiracies and an “overarching” conspiracy among many manufacturers of generic drugs in the United States. Glenmark USA and the other defendants have denied these allegations and have vigorously defended these matters. With a view to resolve this dispute and avoiding uncertainty, Glenmark USA has agreed to enter into a settlement with Humana for the total amount of $15.28 million ($15,285,369), including interest, payable in two installments. The settlement makes clear that Glenmark USA denies each and every one of the allegations made against it and the settlement does not constitute any concession or admission of liability, wrongdoing, or illegality on the part of Glenmark USA. The full amount of the payments under the settlement agreements have been provided for in the Company’s financials. Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com This settlement will not have a significant impact on the financial position of the Company. You are requested to take the above information on your record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com